“…In prior studies conducted in the ANRS HEPAVIH CO-13 cohort, we showed that high coffee intake had the following beneficial effects in HIV-HCV co-infected patients: reduced levels of liver enzymes, including aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) [ 15 ], fewer self-reported side-effects during peg-IFN and ribavirin treatment [ 20 ], and a 50% reduction in mortality risk [ 25 ]. These findings are consistent with those of a meta-analysis of studies on patients with chronic hepatitis C which also showed an inverse relationship between coffee intake and the risk of liver fibrosis [ 7 , 31 , 32 ].…”
Background: Coffee intake has been shown to modulate both the effect of ethanol on serum GGT activities in some alcohol consumers and the risk of alcoholic cirrhosis in some patients with chronic diseases. This study aimed to analyze the impact of coffee intake and alcohol consumption on advanced liver fibrosis (ALF) in HIV-HCV co-infected patients. Methods: ANRS CO13-HEPAVIH is a French, nationwide, multicenter cohort of HIV-HCV-co-infected patients. Sociodemographic, behavioral, and clinical data including alcohol and coffee consumption were prospectively collected using annual self-administered questionnaires during five years of follow-up. Mixed logistic regression models were performed, relating coffee intake and alcohol consumption to ALF. Results: 1019 patients were included. At the last available visit, 5.8% reported high-risk alcohol consumption, 27.4% reported high coffee intake and 14.5% had ALF. Compared with patients with low coffee intake and high-risk alcohol consumption, patients with low coffee intake and low-risk alcohol consumption had a lower risk of ALF (aOR (95% CI) 0.24 (0.12–0.50)). In addition, patients with high coffee intake had a lower risk of ALF than the reference group (0.14 (0.03–0.64) in high-risk alcohol drinkers and 0.11 (0.05–0.25) in low-risk alcohol drinkers). Conclusions: High coffee intake was associated with a low risk of liver fibrosis even in HIV-HCV co-infected patients with high-risk alcohol consumption.
“…In prior studies conducted in the ANRS HEPAVIH CO-13 cohort, we showed that high coffee intake had the following beneficial effects in HIV-HCV co-infected patients: reduced levels of liver enzymes, including aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) [ 15 ], fewer self-reported side-effects during peg-IFN and ribavirin treatment [ 20 ], and a 50% reduction in mortality risk [ 25 ]. These findings are consistent with those of a meta-analysis of studies on patients with chronic hepatitis C which also showed an inverse relationship between coffee intake and the risk of liver fibrosis [ 7 , 31 , 32 ].…”
Background: Coffee intake has been shown to modulate both the effect of ethanol on serum GGT activities in some alcohol consumers and the risk of alcoholic cirrhosis in some patients with chronic diseases. This study aimed to analyze the impact of coffee intake and alcohol consumption on advanced liver fibrosis (ALF) in HIV-HCV co-infected patients. Methods: ANRS CO13-HEPAVIH is a French, nationwide, multicenter cohort of HIV-HCV-co-infected patients. Sociodemographic, behavioral, and clinical data including alcohol and coffee consumption were prospectively collected using annual self-administered questionnaires during five years of follow-up. Mixed logistic regression models were performed, relating coffee intake and alcohol consumption to ALF. Results: 1019 patients were included. At the last available visit, 5.8% reported high-risk alcohol consumption, 27.4% reported high coffee intake and 14.5% had ALF. Compared with patients with low coffee intake and high-risk alcohol consumption, patients with low coffee intake and low-risk alcohol consumption had a lower risk of ALF (aOR (95% CI) 0.24 (0.12–0.50)). In addition, patients with high coffee intake had a lower risk of ALF than the reference group (0.14 (0.03–0.64) in high-risk alcohol drinkers and 0.11 (0.05–0.25) in low-risk alcohol drinkers). Conclusions: High coffee intake was associated with a low risk of liver fibrosis even in HIV-HCV co-infected patients with high-risk alcohol consumption.
“…In the past three decades, caffeine has been related to a lower incidence of chronic liver diseases, such as cirrhosis and hepatocellular carcinoma [289][290][291]. Additionally, in several studies, regular coffee consumption has been significantly associated with reduced hepatic fibrosis related or not with non-alcoholic fatty liver disease [292] and with chronic hepatitis C [293].…”
Section: Caffeine and Liver Diseasesmentioning
confidence: 99%
“…The mechanisms underlying the potential benefits of caffeine have not yet been fully determined. However, some plausible explanations have been suggested [291]. In patients with chronic hepatitis C, a suggested possible mechanism would be the alteration in liver signaling and inflammatory pathways [291].…”
Section: Caffeine and Liver Diseasesmentioning
confidence: 99%
“…However, some plausible explanations have been suggested [291]. In patients with chronic hepatitis C, a suggested possible mechanism would be the alteration in liver signaling and inflammatory pathways [291]. In a rat model, caffeine suppressed connective tissue growth factor expression by interfering with a profibrogenic cytokine, transforming growth factor beta (TGF-β) signaling through the Smad pathway [299].…”
Caffeine (1,3,7-trimethylxanthine) is the most consumed psychoactive substance in the world, acting by means of antagonism to adenosine receptors, mainly A1 and A2A. Coffee is the main natural source of the alkaloid which is quite soluble and well extracted during the brew’s preparation. After consumption, caffeine is almost completely absorbed and extensively metabolized in the liver by phase I (cytochrome P450) enzymes, mainly CYP1A2, which appears to be polymorphically distributed in human populations. Paraxanthine is the major caffeine metabolite in plasma, while methylated xanthines and methyluric acids are the main metabolites excreted in urine. In addition to stimulating the central nervous system, caffeine exerts positive effects in the body, often in association with other substances, contributing to prevention of several chronic diseases. The potential adverse effects of caffeine have also been extensively studied in animal species and in humans. These aspects will be approached in the present review.
“…Even though caffeine contains several chemical components that may provide health benefit in reducing dementia [3], insulin resistance, type 2 diabetes mellitus [4,5], Parkinson disease [5], cirrhosis and advanced hepatic fibrosis [6][7][8][9][10][11], excess intake is not recommended; especially during pregnancy [12]. This is for the fact that caffeine can cross the placenta into the amniotic fluid and fetus and results in adverse pregnancy outcomes.…”
Background The use of excessive caffeine and consumption of alcohol, cigarette, and khat during pregnancy can result in adverse health effects on the fetus. The World Health Organization (WHO) recommends a daily caffeine intake not exceeding 300 mg. Likewise, pregnant women are recommended to avoid alcohol, khat and tobacco use. However, the prevalence's of the use of substances among pregnant women were not well studied in developing countries such as Ethiopia. Therefore, the study aimed to estimate the prevalence of caffeine and alcohol consumption, khat chewing, and tobacco use during pregnancy and identify key factors associated with excess caffeine consumption. Methods We conducted a community based cross-sectional study and used a random sampling technique to recruit 352 pregnant women. We adapted a questionnaire from Caffeine Consumption Questionnaire-Revised (CCQ-R), Alcohol Use Disorder Identification Test (AUDIT), Global Adult Tobacco Survey (GATS), and Ethiopian Demographic Health Survey 2016 for caffeine, alcohol consumption, tobacco use, and khat chewing assessment, respectively. We conducted non-consecutive two days 24-hour recall to determine the habitual intake of caffeine from caffeinated beverages and foods. Prevalence with 95% confidence interval was estimated for excess caffeine intake per day, alcohol consumption, khat chewing, and passive tobacco smoking. We ran a multivariable binary logistic regression model to identify factors associated with excess caffeine intake. Results Almost all pregnant women (98.2%) consumed caffeine as estimated using the 2 days 24hour average. The median daily caffeine intake was 170.5 mg and ranged from 0.00 mg to 549.8 mg per day. In addition, 17.6% (95% CI: 13.9%, 22.0%) of them had a daily caffeine consumption of 300 mg and above exceeding the WHO recommended daily caffeine intake
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.